J Allergy Clin Immunol Pract
August 2020
Background: Cholinergic urticaria (UCOL) is a highly disabling inducible urticaria triggered by an increase in core body temperature.
Objective: To explore the safety and efficacy of omalizumab in controlling UCOL.
Methods: We conducted a multicenter randomized mixed double-blind and open-label (first 4 months blinded followed by 8 months open-label) placebo-controlled clinical trial in 22 patients suffering from UCOL who were unresponsive to a double dose of antihistamines.
Intraoral contact allergy reactions are clinically poorly differentiated and understood, and are not very commonly described in the specialized literature. Although such reactions appear to be scantly relevant, evidence suggests that they may be more frequent than previously believed. No single or specific clinical picture of intraoral contact allergy exists, though lichenoid reactions appear to be the most common manifestations.
View Article and Find Full Text PDF